Imamura K. Chiyo

J-GLOBAL         Last updated: Nov 8, 2019 at 12:17
 
Avatar
Name
Imamura K. Chiyo
E-mail
imamurackmed.showa-u.ac.jp
Affiliation
Showa University
Section
Advanced Cancer Translational Research Institute
Job title
Associate Professor
Degree
PhD(Kumamo University)
Research funding number
00570954

Research Areas

 
 

Academic & Professional Experience

 
Mar 2019
 - 
Today
Associate Professor, Advanced Cancer Translational Research Institute, Showa University
 
Mar 2019
 - 
Today
Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University
 
2015
 - 
Feb 2019
臨床研究推進センター教育・研修部門, Keio University Hospital
 
Jan 2009
 - 
Feb 2019
Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine
 
Jan 2017
 - 
Today
客員研究員, イノベーション推進センター杉山特別研究室, 理化学研究所
 

Education

 
Apr 1997
 - 
Mar 2000
Doctoral course, Graduate School of Pharmaceutical Sciences, Kumamoto University
 
Apr 1987
 - 
Mar 1989
Master Course, Graduate School of Pharmaceutical Sciences, Kumamoto University
 
Apr 1983
 - 
Mar 1987
Pharmaceutical Science, Kumamoto University
 

Published Papers

 
Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study
Yamazaki K, Matsumoto S, Imamura CK, Yamagiwa C, Shimizu A, Yoshino T
Jpn J Clin Oncol      Oct 2019   [Refereed]
Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y, Kozuki T, Miura S, Sasaki T, Tamiya A, Teraoka S, Tsubata Y, Yoshioka H, Hattori Y, Imamura CK, Katsuya Y, Matsui R, Minegishi Y, Mizugaki H, Nosaki K, Okuma Y, Sakamoto S, Sone T, Tanaka K, Umemura S, Yamanaka T, Amano S, Hasegawa K, Morita S, Nakajima K, Maemondo M, Seto T, Yamamoto N
International journal of clinical oncology   24(7) 731-770   Jul 2019   [Refereed]
Imamura K. Chiyo
Drug Metab Pharmacokinet   34(1) 14-18   Feb 2019   [Refereed][Invited]
Miura Y, Imamura CK, Uchino K, Kishida T, Matsubara N, Shinojima T, Kondo K, Hongo F, Yoshimura K, Tanigawara Y, Takano T
Clinical genitourinary cancer   17(1) e1-e11   Feb 2019   [Refereed]
Yamauchi T, Fernandez JRE, Imamura CK, Yamauchi H, Jinno H, Takahashi M, Kitagawa Y, Nakamura S, Lim B, Krishnamurthy S, Reuben JM, Liu D, Tripathy D, Chen H, Takebe N, Saya H, Ueno NT
Oncotarget   9(6) 6872-6882   Jan 2018   [Refereed]

Misc

 
Clinical Studies for Development of Individualized Medicine Based on Clinical Pharmacologu
Imamura CK
Japanese Journal of Breast Cancer (in Japanese)   33(3) 235-243   Jun 2018   [Invited]
Imamura CK
Farumashia (in Japanese)   53(4) 338-342   Apr 2017   [Invited]
Pharmacokinetics and clinical pharmacology of immune checkpoint inhibitors.
Imamura CK
Clinical Oncology (in Japanese)   19(1) 97-100   Jan 2017   [Invited]
PK/PD study for individualized dose optimaization of axitinib based on TDM
Miura Yuji, Imamura Chiyo, Tanigawara Yusuke
Recent Advances in Clinical Pharmacology   179-185   2016
PK/PD relationship and TDM of molecular targeting drugs.
Imamura CK
Clinical Oncology (in Japanese)   18(1) 79-85   Jul 2016   [Invited]

Books etc

 
The Role of pharmacist for leukemia treatment: In handbook of leukemia treatment for medical staff.
Imamura CK
Chugai Igaku Publishing (in Japanese)   Oct 2017   
チームで学ぶ女性がん患者のためのホルモンマネジメント
今村 知世
篠原出版新社(東京)   Jul 2017   
Renal Cell Carcinoma
Imamura CK
Springer   Jan 2017   ISBN:978-4-431-55531-5
抗がん薬の臨床薬理
今村 知世,谷川原 祐介
南山堂(東京)   Jul 2015   
腎臓病薬物療法専門・認定薬剤師テキスト
Imamura Chiyo
じほう(東京)   May 2013   

Conference Activities & Talks

 
What we learned from the tamoxifen pharmacogenomics study [Invited]
Imamura CK, Tanigawara Y
Oct 2019   
Phase I study of afatinib plus bevacizumab in patients with advanced non-small cell lung cancer harboring EGFR mutations
Tokito T, Ko R, Imamura CK, Shukuya T, Shimada N, Koyama R, Yamada K, Ishii H, Azuma K, Takahashi K
IASLC 2019 World Conference on Lung Cancer   Sep 2019   
Anticancer drug treatment in patients with hepatic impairment [Invited]
Imamura K. Chiyo
JSMO Annual Meeting   Jul 2019   
mpact of interaction with acid-reducing agents on efficacy of erlotinib in patients with advanced EGFR-mutated NSCLC
Imamura CK, Kenmotsu H, Kawamura T, Oyakawa T, Ono A, Omori S, Nakashima K, Wakuda K, Taira T, Naito T, Murakami H, Yamamoto N, Takahashi T, Tanigawara Y
JSMO Annual Meeting   Jul 2019   
Exposure-response analysis of S-1 in patients with advanced gastric cancer
2. Takeuchi M, Imamura CK, Booka E, Kasai H, Kawakubo H, Boku N, Tanigawara Y, Kitagawa Y
JSMO Annual Meeting   Jul 2019   

Works

 
Exposure-response(PK/PD)relationshipに基づいた抗がん薬の個別化投与
Imamura K. Chiyo   The Others   Aug 2018 - Aug 2018
PK/PD relationship(Exposure-Response relationship)~小児における応用と今後の展望~
Imamura K. Chiyo   The Others   Jul 2018 - Jul 2018
春のふれあい座談会
Imamura K. Chiyo   The Others   Sep 2017
Exposure-response analysis of erlotinib for individualized dosing based on TDM
Imamura K. Chiyo   The Others   Sep 2017 - Sep 2017
スペシャル・ポピュレーションへのがん薬物療法
Imamura K. Chiyo   The Others   Sep 2017 - Sep 2017

Research Grants & Projects

 
高齢者がん診療指針策定に必要な基盤整備に関する研究
MHLW: Health and Labour Sciences Research Grants
Project Year: 2018       Investigator(s): Kazuo Tamura
小児Ph染色体陽性白血病に対するチロシンキナーゼ阻害薬の適正使用に関する研究開発
AMED: 
Project Year: Oct 2018 - Mar 2021    Investigator(s): Hiroyuki Shimada
革新的がん医療実用化研究事業
Development of individualized medicine by exposure matching based on key determinant of pharmacokinetics
Grant-in-Aid for Scientific Research
Project Year: Apr 2017 - Mar 2020
非小細胞肺癌患者に対するEGFR-TKIsの治療薬物モニタリング確立のための研究
Grant-in-Aid for Scientific Research
Project Year: Apr 2016 - Mar 2019
治験活性化に資するGCP運用等に関する研究
Japan Agency for Medical Research and Development (AMED): 
Project Year: Apr 2015 - Mar 2016

Patents

 
特開平5-213752 : オメプラゾール含有坐剤の調製